Outcome of treatment with Triheptanoin in pediatric patients with long chain fatty acid oxidation disorders (LCFAODs)

Outcome of treatment with Triheptanoin in pediatric patients with long chain fatty acid oxidation disorders (LCFAODs) at Queen Sirikit National Institute of Child Health.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20210604002

Enrollment

Registered

2021-06-04

Start date

2021-06-30

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

long chain fatty acid oxidation disorders (LCFAODs) long chain fatty acid oxidation disorders (LCFAODs), outcome, treatment

Interventions

patient with long chain fatty acid oxidation disorders (LCFAODs)

Treatment

patient

Eligibility

Sex/Gender

All

Age

2 Weeks to 15 Years

Inclusion criteria

Inclusion criteria: Patient with diagnosis of long chain fatty acid oxidation disorders (LCFAODs)

Exclusion criteria

Exclusion criteria: can not continue treatment until the end of research

Design outcomes

Primary

Measure	Time frame
frequency of hospitalization with rhabdomyolysis 2 years number	—

Secondary

Measure	Time frame
abnormality of the cardiac muscles 2 years echo	—

Countries

Thailand

Contacts

Public ContactDuenchai khata

Queen Sirikit National Institute of Child Health

dueanchai_khata@hotmail.com0891599650

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026